Literature DB >> 8910914

Prevention of photocarcinogenesis by topical administration of pure epigallocatechin gallate isolated from green tea.

H L Gensler1, B N Timmermann, S Valcic, G A Wächter, R Dorr, K Dvorakova, D S Alberts.   

Abstract

Topical application of purified (-)-epigallocatechin-3-gallate (EGCG), a polyphenolic antioxidant isolated from green tea, inhibited photocarcinogenesis in BALB/cAnNHsd mice with no visible toxicity. Mice were treated with 0, 10, or 50 mg of EGCG in 200 microliters of acetone three times weekly for three weeks before ultraviolet (UV) treatments began and throughout the experiment. UV radiation consisted of five 30-minute exposures per week to banks of six FS40 Westinghouse sunlamps for 25 weeks. In the photocarcinogenesis study, mice received a total dose of approximately 2.1 x 10(6) J/m2. Skin cancer incidence in UV-irradiated mice was 96% at 28 weeks after the first UV treatment; EGCG at 10 or 50 mg reduced this incidence to 62% and 29%, respectively. UV-induced immunosuppression, assessed by the inability of UVB-irradiated mice to reject a syngeneic antigenic tumor, was not influenced by topical EGCG. Oral administration of 0, 100, or 500 mg of pure EGCG per liter of drinking water (approximately 0, 0.56, or 2.8 mg/day, respectively) did not decrease UV-induced skin tumor incidence, rate of primary tumor growth, or inability to reject antigenic tumors. Thus induction of skin tumors by UV radiation was significantly reduced by topical, but not by oral, administration of purified EGCG through a mechanism distinct from inhibition of photoimmunosuppression.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8910914     DOI: 10.1080/01635589609514488

Source DB:  PubMed          Journal:  Nutr Cancer        ISSN: 0163-5581            Impact factor:   2.900


  14 in total

1.  Application of phase-trafficking methods to natural products research.

Authors:  Juan J Araya; Gloria Montenegro; Lester A Mitscher; Barbara N Timmermann
Journal:  J Nat Prod       Date:  2010-09-24       Impact factor: 4.050

2.  Theaflavin-3, 3'-digallate induces epidermal growth factor receptor downregulation.

Authors:  Hideya Mizuno; Yong-Yeon Cho; Feng Zhu; Wei-Ya Ma; Ann M Bode; Chung S Yang; Chi-Tang Ho; Zigang Dong
Journal:  Mol Carcinog       Date:  2006-03       Impact factor: 4.784

Review 3.  Prevention of non-melanoma skin cancer.

Authors:  S P Stratton
Journal:  Curr Oncol Rep       Date:  2001-07       Impact factor: 5.075

Review 4.  The challenge of developing green tea polyphenols as therapeutic agents.

Authors:  C Huo; S B Wan; W H Lam; L Li; Z Wang; K R Landis-Piwowar; D Chen; Q P Dou; T H Chan
Journal:  Inflammopharmacology       Date:  2008-10       Impact factor: 4.473

Review 5.  Epigallocatechin 3-gallate and green tea catechins: United they work, divided they fail.

Authors:  Ann M Bode; Zigang Dong
Journal:  Cancer Prev Res (Phila)       Date:  2009-05-26

6.  Exceptionally high protection of photocarcinogenesis by topical application of (--)-epigallocatechin-3-gallate in hydrophilic cream in SKH-1 hairless mouse model: relationship to inhibition of UVB-induced global DNA hypomethylation.

Authors:  Anshu Mittal; Chandrika Piyathilake; Yukihiko Hara; Santosh K Katiyar
Journal:  Neoplasia       Date:  2003 Nov-Dec       Impact factor: 5.715

Review 7.  The role of phytonutrients in skin health.

Authors:  Julie A Evans; Elizabeth J Johnson
Journal:  Nutrients       Date:  2010-08-24       Impact factor: 5.717

8.  Skin Protective Effect of Epigallocatechin Gallate.

Authors:  Eunji Kim; Kyeonghwan Hwang; Jongsung Lee; Sang Yun Han; Eun-Mi Kim; Junseong Park; Jae Youl Cho
Journal:  Int J Mol Sci       Date:  2018-01-06       Impact factor: 5.923

Review 9.  Antioxidants in dermatology.

Authors:  Flavia Alvim Sant'anna Addor
Journal:  An Bras Dermatol       Date:  2017 May-Jun       Impact factor: 1.896

10.  Does the consumption of green tea reduce the risk of lung cancer among smokers?

Authors:  Wenbin Liang; Colin W Binns; Le Jian; Andy H Lee
Journal:  Evid Based Complement Alternat Med       Date:  2006-10-24       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.